Aspire Biopharma files patent application for sublingual drug delivery platform

Aspire Biopharma (ASBP) announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application – which seeks patent protection of Aspire’s proprietary technology in a variety of classes of drugs and other substances–focuses exclusively on protecting the Company’s advanced sublingual drug delivery system, which is designed to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients and other substances into the bloodstream, increasing bioavailability and improving speed of onset. An omnibus claim is a statement in a patent application that describes the unique features of an invention and defines the scope of protection for the patent. It is a formal way of summarizing the points of novelty of the invention and is usually followed by a fixed form. The omnibus patent can provide IP protection in new areas/classes in addition to the patents already filed by Aspire.